First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.